Zobrazeno 1 - 10
of 383
pro vyhledávání: '"Hilde, Rosing"'
Autor:
Karen de Jong, David Damoiseaux, Dick Pluim, Hilde Rosing, Jos H. Beijnen, Hans van Thienen, Thomas P.C. Dorlo, Alwin D.R. Huitema, Frédéric Amant
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115354- (2023)
Nivolumab is an immunotherapeutic monoclonal antibody (mAb) that is used for the treatment of several types of cancer. The evidence on its use during lactation is lacking. Here, we report on a 39-year-old woman with metastasized melanoma who was trea
Externí odkaz:
https://doaj.org/article/a6d2187b2f694b489900d86979fdf8cf
Autor:
Changpei Gan, Jing Wang, Alejandra Martínez-Chávez, Michel Hillebrand, Niels de Vries, Joke Beukers, Els Wagenaar, Yaogeng Wang, Maria C. Lebre, Hilde Rosing, Sjoerd Klarenbeek, Rahmen Bin Ali, Colin Pritchard, Ivo Huijbers, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 2, Pp 618-631 (2023)
The mammalian carboxylesterase 1 (Ces1/CES1) family comprises several enzymes that hydrolyze many xenobiotic chemicals and endogenous lipids. To investigate the pharmacological and physiological roles of Ces1/CES1, we generated Ces1 cluster knockout
Externí odkaz:
https://doaj.org/article/87e193186c58427c9b561d417264b90f
Autor:
Changpei Gan, Jing Wang, Yaogeng Wang, Alejandra Martínez-Chávez, Michel Hillebrand, Niels de Vries, Joke Beukers, Maria C. Lebre, Els Wagenaar, Hilde Rosing, Sjoerd Klarenbeek, Onno B. Bleijerveld, Ji-Ying Song, Maarten Altelaar, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 164, Iss , Pp 114956- (2023)
Mammalian carboxylesterase 1 enzymes can hydrolyze many xenobiotic chemicals and endogenous lipids. We here identified and characterized a mouse strain (FVB/NKI) in which three of the eight Ces1 genes were spontaneously deleted, removing Ces1c and Ce
Externí odkaz:
https://doaj.org/article/6feb859d901d4d4c97531a2a7f1a6338
Autor:
Stacey E. P. Joosten, Marius Wellenstein, Rutger Koornstra, Annelot van Rossum, Joyce Sanders, Vincent van der Noort, Maria C. Ferrandez, Rolf Harkes, Ingrid A. M. Mandjes, Hilde Rosing, Alwin Huitema, Jos H. Beijnen, Jelle Wesseling, Paul J. van Diest, Hugo M. Horlings, Sabine C. Linn, Wilbert Zwart
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Window studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tumor cell positivity for the proliferation marker Ki67 is often used as a proxy for treatment response. Immunohistochemistry (IHC)-based Ki67 o
Externí odkaz:
https://doaj.org/article/d14fa82c2abe4ab4ace6a27f694de818
Publikováno v:
Drugs in R&D, Vol 20, Iss 2, Pp 147-154 (2020)
Abstract With increasing numbers of drugs tested in oncology for smaller patient populations, fewer patients are available to answer important clinical pharmacological questions in the timeframe of clinical drug development. The quality and efficienc
Externí odkaz:
https://doaj.org/article/7cba2b9f11e34db58c4ceb57fa0be666
Autor:
Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 940-950 (2019)
Capecitabine is an oral prodrug of the anticancer drug 5‐fluorouracil (5‐FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5′‐deoxy‐5‐fluorocytidine (dFCR), 5′‐deoxy‐5‐
Externí odkaz:
https://doaj.org/article/8300a5fe4be74766ad22f7c77488aab7
Autor:
Jeroen J. M. A. Hendrikx, Frederik E. Stuurman, Ji‐Ying Song, Vincent A. deWeger, Jurjen S. Lagas, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel, Jan H. M. Schellens, Serena Marchetti
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Abstract Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose‐limiting toxicity. This study com
Externí odkaz:
https://doaj.org/article/312864ef1c70464298e06dea8e715675
Autor:
Laura Molenaar-Kuijsten, Milan van Meekeren, Remy B. Verheijen, Judith V. M. G. Bovée, Marta Fiocco, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Aisha B. Miah, Hans Gelderblom, Rick L. M. Haas, Neeltje Steeghs
Publikováno v:
Cancers, Vol 13, Iss 22, p 5780 (2021)
There is a lack of understanding whether plasma levels of anticancer drugs (such as pazopanib) correlate with intra-tumoral levels and whether the plasma compartment is the best surrogate for pharmacokinetic and pharmacodynamic evaluation. Therefore,
Externí odkaz:
https://doaj.org/article/c3f1d4b3365f4a8dad8a15b3f5a71773
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
Autor:
Imke H. Bartelink, Brendan Prideaux, Gregor Krings, Lisa Wilmes, Pei Rong Evelyn Lee, Pan Bo, Byron Hann, Jean-Philippe Coppé, Diane Heditsian, Lamorna Swigart-Brown, Ella F. Jones, Sergey Magnitsky, Ron J Keizer, Niels de Vries, Hilde Rosing, Nela Pawlowska, Scott Thomas, Mallika Dhawan, Rahul Aggarwal, Pamela N. Munster, Laura J. Esserman, Weiming Ruan, Alan H. B. Wu, Douglas Yee, Véronique Dartois, Radojka M. Savic, Denise M. Wolf, Laura van ’t Veer
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-17 (2017)
Abstract Background Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some
Externí odkaz:
https://doaj.org/article/36493b79564d44c2b1b8ca3d6cd7f195
Autor:
Marit A. C. Vermunt, Merel van Nuland, Lisa T. van der Heijden, Hilde Rosing, Jos. H. Beijnen, Andries M. Bergman
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:785-793
Purpose Recently, docetaxel treatment of metastatic prostate cancer patients shifted towards the hormone-sensitive stage of the disease. There are contradictive reports on differences in toxicity of docetaxel in metastatic hormone-sensitive prostate